ArticleDiabetologia2026
Staging intermediate hyperglycaemia for type 2 diabetes prevention: the ELSA-Brasil study.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aims/hypothesisWe aimed to evaluate stages in the development of type 2 diabetes by combining fasting plasma glucose (FPG) with 1 h plasma glucose (PG) or HbA
methodsUsing data of 1174 middle- and older-aged Brazilian adults from the Rio Grande do Sul centre of the ELSA-Brasil cohort, 2017 to 2024, we developed stages based on previously recommended thresholds of mild (FPG: 5.6-6.0 mmol/l; 1 h PG: 6.7-8.5 mmol/l) and moderate (FPG: 6.1-6.9 mmol/l; 1 h PG: 8.6-11.5 mmol/l) hyperglycaemia. Similarly, we developed stages combining FPG levels with mild (39-41 mmol/mol; 5.7-5.9%) or moderate (42-46 mmol/mol; 6.0-6.4%) HbA
resultsThe FPG/1 h PG schema stratified participants into three stages of decreasing ISSI-2 levels and increasing frequency of high risk for complications. The relative risk of incident diabetes increased progressively up to stage 3 in crude and adjusted models (15.4 [95% CI 6.1, 38.8] and 11.4 [4.5, 18.0]), respectively. This schema achieved 89.1% sensitivity and 53.7% specificity in the prediction of incident diabetes. When staging was applied with the clinical score, specificity improved (60.3%), and the need for laboratory testing decreased by 27.1%. The lower frequency of altered HbA CONCLUSIONS/
interpretationFPG/1 h PG schemas resulted in a nuanced stratification of intermediate hyperglycaemia, with superior prognostic properties compared with FPG/HbA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.